
Please try another search
Bernstein analysts said Wednesday that they see compelling upside in Outperform-rated Centene (NYSE:CNC) at its current valuation.
The analysts, who have a $92 price target on the stock, take the view as "Redetermination uncertainty is reduced over the summer."
"We believe the company is attractive based on our long-term outlook for growth in this sector, excessive pessimism about the impacts of Redetermination (or kicking people off Medicaid post-COVID), and the company's value creation plan to harvest cost savings from recent growth," wrote the analysts.
"Redetermination appears priced into the stock - 2023 has been a challenging year for stocks with material exposure to Medicaid, with CNC down 20+% YTD, due to concerns about the impact of redeterminations," they added.
Bernstein also believes that Medicaid is an attractive long-term growth sector, and should receive a market multiple over time, while the analysts also noted that CNC's "current relative valuations are near historic lows."
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.